Research and development Service
Swalife Healthcare R&D Services
Welcome to Swalife Healthcare, where our ground breaking research and development services are paving the way for advancements in medical science and drug discovery. With a commitment to excellence and innovation, we offer a comprehensive suite of services designed to meet the complex needs of today’s healthcare challenges.
Our Services










OUR Services
Network pharmacology, molecular docking, and deep learning are innovative approaches that have significantly advanced drug discovery processes.
1- Network Pharmacology:
Performing network pharmacology involves a systematic approach to understanding the interactions between biological entities such as genes, proteins, and metabolites in a network context. Here is a general procedure to conduct network pharmacology:
- Define Research Objectives:
Clearly define the research objectives and questions you want to address using network pharmacology. Identify the specific disease, pathway, or biological process of interest. - Data Collection:
Gather relevant data from various sources, including biological databases, literature, and omics datasets. Collect information on genes, proteins, metabolites, diseases, and drug compounds related to your research. - Network Construction:
Build molecular interaction networks based on the collected data. Common types of networks include protein-protein interaction (PPI) networks, gene-disease networks, and drug-target interaction networks.
Utilize bioinformatics tools and databases to construct these networks, considering the reliability of the interactions. - Network Analysis:
Conduct network analysis to identify key nodes (genes, proteins, or metabolites) and edges (interactions) within the network.
Employ network parameters such as centrality measures (degree, betweenness, closeness) to assess the importance of nodes in the network. - Pathway Analysis:
Perform pathway analysis to identify enriched biological pathways associated with the genes or proteins in the network. This helps to understand the functional context of the network. - Disease Association Analysis:
Explore the relationship between the identified network components and specific diseases. Analyze how genes or proteins in the network are linked to the disease of interest. - Drug-Target Interaction Analysis:
Investigate drug-target interactions within the network. Identify potential drugs that target key nodes in the network and assess their relevance to the studied disease. - Integration of Omics Data:
Integrate omics data, such as genomics, transcriptomics, and metabolomics, into the network analysis to gain a comprehensive understanding of the biological system. - Visualization:
Visualize the constructed networks using network visualization tools. Visualization aids in interpreting complex relationships within the network. - Validation:
Validate the findings using experimental data or by comparing them with existing literature. This step ensures the reliability and relevance of the network pharmacology results. - Interpretation and Conclusion:
Interpret the results in the context of the original research objectives. Summarize the key findings and draw conclusions about the relationships between the biological entities in the studied system.
Send your enquiry on email- info@swalifehealthcare or call to discuss on 08069640971
2- Molecular Docking:
- Ligand and Protein Preparation:
Pyrx and Discovery Studio: Import and prepare the ligand and protein structures.
Add hydrogen atoms, assign charges, and optimize the geometry.
SwissADME: Ensure the ligand and protein structures are in an appropriate format (e.g., PDB, SDF).
SwissADME primarily focuses on predicting ADME properties, but it can analyze ligand structures for drug-likeness.
- Search Space Definition:
Define the region in the protein where docking calculations will be performed. This is typically the binding site or a specified area around it.
Adjust the search space based on the characteristics of the ligand and known binding interactions.
- Docking Algorithm and Scoring Function:
Pyrx and Discovery Studio: Choose an appropriate docking algorithm (e.g., AutoDock, Vina) and a scoring function to evaluate the binding affinity.
SwissADME: SwissADME primarily focuses on drug-likeness predictions and does not perform molecular docking calculations. It evaluates molecular descriptors and predicts ADME properties.
- Running Docking Calculations:
Initiate the docking simulation, allowing the software to perform the calculations.
Specify parameters such as the number of poses to generate and the level of precision.
- Result Analysis:
Pyrx and Discovery Studio: Analyze the docking results, considering factors such as binding energy, binding pose, and interactions with the target protein.
Use visualization tools to explore the 3D structures of the docked complexes.
SwissADME: Analyze the ADME properties predicted by SwissADME, including absorption, distribution, metabolism, and excretion characteristics.
- Refinement (If Necessary):
Refine and optimize the binding poses if the docking results suggest the need for adjustments.
Use software tools or additional simulations to improve the accuracy of the docking predictions.
- Interpretation and Validation:
Interpret the results in the context of the research objectives and known biological interactions.
Validate the results through comparisons with experimental data or known binding modes.
- Reporting and Visualization:
Generate reports summarizing the key findings of the molecular docking study.
Create visual representations of the docked complexes and interactions for presentation or publication.
- SwissADME Drug-Likeness Analysis:
For SwissADME, focus on drug-likeness predictions, which include Lipinski’s Rule of Five, bioavailability radar, and other molecular descriptors.
SwissADME can help assess whether a compound possesses drug-like properties based on its physicochemical characteristics.
- Integration with Other Tools:
Integrate the results from molecular docking with other bioinformatics tools and databases for a comprehensive analysis.
Cross-validate findings using multiple computational approaches or experimental data when possible.
These principles provide a general guideline for performing molecular docking using Pyrx, Discovery Studio, and SwissADME. It’s essential to adapt the workflow based on the specific requirements of your research and the capabilities of the chosen software.
Send your enquiry via email to- info@swalifehealthcare or call to discuss on 08069640971
3. Deep Learning:
One of the key strengths of deep learning lies in its ability to handle intricate and high-dimensional data, such as molecular and genomic information, with a remarkable level of precision. This enables researchers to uncover subtle patterns and associations that may be crucial in understanding the biological mechanisms underlying diseases and their potential treatments.
In drug discovery, deep learning models excel at tasks such as predicting the bioactivity of compounds, elucidating intricate interactions between drugs and biological targets, and forecasting potential toxicities associated with candidate molecules. By leveraging these capabilities, researchers can significantly enhance the efficiency of the drug development pipeline, accelerating the identification and optimization of promising compounds.
Furthermore, deep learning facilitates the analysis of diverse types of biological data, including omics data (genomics, proteomics, metabolomics), structural biology information, and clinical data. Integrating these various data sources allows for a comprehensive understanding of the complex interplay between drugs and biological systems, paving the way for more informed and targeted drug development strategies.
In essence, the application of deep learning in drug discovery represents a paradigm shift, ushering in an era where computational methods can navigate and make sense of the vast and intricate landscape of molecular information. This transformative approach holds the promise of not only expediting the drug discovery process but also uncovering novel therapeutic avenues that may have eluded traditional methodologies. As the field continues to evolve, the synergy between deep learning and drug development is poised to redefine the landscape of pharmaceutical research and bring about innovative solutions for treating a wide array of diseases.
Send your enquiry via email to- info@swalifehealthcare or call to discuss on 08069640971
4. Semisynthetic Compounds:
Semisynthesis is a transformative method in drug discovery that entails the modification of natural compounds through chemical processes, resulting in derivatives with enhanced pharmacological properties. This approach is instrumental in optimizing key characteristics of drug candidates, including bioavailability, potency, and safety profiles.
In the realm of drug development, natural compounds often serve as valuable starting points. These compounds, derived from plants, microorganisms, or other natural sources, may exhibit promising pharmacological activities but might also possess limitations in terms of efficacy, stability, or other factors. Semisynthesis offers a strategic solution to overcome these limitations by introducing targeted chemical modifications.
Key Aspects of Semisynthesis in Drug Discovery:
Chemical Modification: Semisynthesis involves the strategic alteration of the chemical structure of a natural compound through synthetic processes.
Optimization of Bioavailability: Natural compounds may have suboptimal bioavailability, hindering their effectiveness as drugs.
Potency Enhancement: Semisynthesis allows for the enhancement of the pharmacological potency of natural compounds.
Safety Profile Optimization: Safety concerns, such as toxicity or adverse effects, can be addressed through semisynthesis.
Diversity of Derivatives: Semisynthesis offers a versatile approach to generate a library of derivatives from a single natural compound.
Drug Design Flexibility: The flexibility of semisynthesis facilitates the design of compounds with specific attributes tailored to the requirements of a drug development project.
Researchers can harness the diversity of natural compounds and enhance their therapeutic potential through chemical modifications, facilitating the development of novel drugs with tailored characteristics.
Send your enquiry via email to- info@swalifehealthcare or call to discuss on 08069640971
5. Nanotechnology:
Nanotechnology involves the manipulation of materials at the nanoscale, often in the range of 1 to 100 nanometers. In drug development, nanotechnology plays a pivotal role in drug delivery systems.
Nano-sized carriers, such as liposomes, nanoparticles, and nanotubes, enable targeted drug delivery to specific tissues or cells, enhancing therapeutic efficacy while minimizing side effects. Additionally, nanocarriers can improve drug solubility, stability, and sustained release profiles.
Integration of Semisynthesis and Nanotechnology:
Combining semisynthetic compounds with nanotechnology presents a synergistic approach to drug discovery. Semisynthetic modifications can be tailored to enhance the compatibility of drugs with nano-sized carriers. This integration enables the design of multifunctional drug delivery systems, where semisynthetic modifications optimize the drug’s pharmacological properties, while nanotechnology facilitates controlled and targeted release.
Advantages of Integration:
Targeted Delivery: Nanocarriers can transport semisynthetic drugs precisely to the site of action, increasing therapeutic efficacy and reducing off-target effects.
Improved Bioavailability: Semisynthetic modifications can enhance the bioavailability of drugs, while nanocarriers address challenges related to drug solubility and stability.
Personalized Medicine: The combined approach allows for the development of personalized treatment strategies by tailoring drug formulations to individual patient needs.
Challenges:
Despite the potential advantages, challenges such as scalability, safety, and regulatory considerations must be carefully addressed when integrating semisynthetic compounds and nanotechnology in drug development. However, ongoing research and advancements in both fields hold great promise for overcoming these challenges and revolutionizing the landscape of drug discovery and therapeutics.
6. Cell studies in drug discovery
7. Use of chicken eye, brine shrimp, earth worm, Yeast and Bacteria to study toxicity
8. Caenorhabditis elegans (C. elegans) and Fruit Fly (Drosophila melanogaster) in Toxicity Studies:
9. Use of the animal model to study acute, chronic toxicity as per OCED and bioactivity study on DMBA induced cancer
10. Earthworm (Eisenia fetida) Assay:
11. Allium cepa Assay (Onion Root Tip Assay):